StartseiteAVDL • NASDAQ
add
Avadel Pharmaceuticals PLC
Letzter Kursschluss
7,90 $
Preisspanne heute
7,80 $ - 8,35 $
Preisspanne im Jahr
7,39 $ - 19,09 $
Marktkapitalisierung
759,81 Mio. USD
Durchschnittliches Volumen
1,33 Mio.
KGV
-
Dividendenrendite
-
Primärbörse
NASDAQ
Aktuelle Nachrichten
Finanzdaten
Gewinn- und Verlustrechnung (GuV)
Umsatz
Nettogewinn
| (USD) | Sept. 2024info | Veränd. Jahresvgl. |
|---|---|---|
Umsatz | 50,02 Mio. | 613,22 % |
Betriebskosten | 44,20 Mio. | 5,21 % |
Nettogewinn | -2,62 Mio. | 92,76 % |
Nettoumsatzrendite | -5,25 | 98,98 % |
Gewinn je Aktie | -0,03 | 92,68 % |
EBITDA | 708.000,00 | 102,05 % |
Effektiver Steuersatz | -3,47 % | — |
Bilanz
Gesamtvermögen
Gesamtverbindlichkeiten
| (USD) | Sept. 2024info | Veränd. Jahresvgl. |
|---|---|---|
Bar- und kurzfr. Invest. | 65,81 Mio. | -57,04 % |
Gesamtvermögen | 158,25 Mio. | -22,08 % |
Gesamtverbindlichkeiten | 83,59 Mio. | -10,07 % |
Gesamtkapital | 74,66 Mio. | — |
Ausgegebene Aktien | 96,36 Mio. | — |
Kurs-Buchwert-Verhältnis | 10,13 | — |
Gesamtkapitalrentabilität | -0,52 % | — |
Kapitalrendite | -0,73 % | — |
Cashflow
Zahlungswirksame Veränderung des Finanzmittelbestands
| (USD) | Sept. 2024info | Veränd. Jahresvgl. |
|---|---|---|
Nettogewinn | -2,62 Mio. | 92,76 % |
Operativer Cashflow | -6,89 Mio. | 81,98 % |
Barmittel aus Invest. | 4,93 Mio. | -49,80 % |
Barmittel aus Finanzierung | 1,18 Mio. | -96,14 % |
Zahlungswirksame Veränderung des Finanzmittelbestands | -265.000,00 | -114,51 % |
Ungehinderter Cashflow | -9,99 Mio. | 64,96 % |
Info
Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
The company was founded as Flamel Technologies SA in Lyon, France in 1990.
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.
On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.
On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.
In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.
In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate. Wikipedia
Gegründet
1990
Website
Mitarbeiter
154
